Plain-English translation of NCT07290894 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a Phase 2 trial testing two medications called and Lenvatinib together to treat vulvar cancer in women. The trial is enrolling about 80 patients with different stages of vulvar cancer — some with tumors that cannot be surgically removed, others with cancer that has spread or returned. Researchers want to see how well this combination works and whether it is safe.
Vulvar cancer is rare and treatment options are limited, especially for advanced cases. This trial exists to find out if this medication combination can help patients whose cancer cannot be treated with surgery alone or has already come back after chemotherapy.
You likely qualify if…
You likely don't qualify if…
Depending on which group you join, you will receive both medications together as intravenous infusions and oral pills, typically given over several weeks in treatment cycles. If your cancer responds well, you may continue with one of the medications alone for maintenance therapy, which could last many months. You will have regular blood tests, imaging scans, and clinic visits to monitor how you are responding and to check for any side effects.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
Italy
Phase
Testing effectiveness
Sponsor
National Cancer Institute, Naples
Enrollment target
~80 participants
Started
March 2026
Primary completion
October 2031
Age range
18 Years and older
Sex
Female only
Last updated on clinicaltrials.gov in April 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Clorinda Schettino, MD
National Cancer Institute,IRCCS, Fondazione G. Pascale, Naples , Italy
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.